Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren’s syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Metrics to compare | TRIB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTRIBPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −30.8x | −0.6x | |
PEG Ratio | −0.02 | 0.00 | 0.00 | |
Price/Book | −0.5x | 2.9x | 2.6x | |
Price / LTM Sales | 0.2x | 2.6x | 3.1x | |
Upside (Analyst Target) | - | 19.5% | 54.8% | |
Fair Value Upside | Unlock | −13.7% | 7.9% | Unlock |